Skip to main content

Advertisement

Table 1 Baseline characteristics of 532 patients with non–small cell lung cancer (NSCLC)

From: Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21

Characteristic No. of patients Exon 19 deletion Exon 21 L858R mutation P valueb
Total 532 319 213  
Agea (years)     0.001
 Median 59 57 61  
 Range 20–86 20–86 31–81  
Sex     0.068
 Male 210 136 74  
 Female 322 183 139  
Smoking status     0.931
 Never smoker 365 220 145  
 Ever smoker 145 88 57  
 Unknown 22 11 11  
ECOG PS     0.202
 0 117 58 59  
 1 292 178 114  
 2 26 15 11  
 3 8 4 4  
Not evaluated 89 64 25  
Clinical stage     0.572
 IIIB 28 14 14  
 IV 495 301 194  
 Unknown 9 4 5  
EGFR-TKI     0.270
 Gefitinib 369 210 159  
 Erlotinib 82 56 26  
 Icotinib 56 34 22  
 Unknown 25 19 6  
TKI line     0.004
 Maintenance 11 1 10  
 Line 1 280 157 123  
 Line 2 173 118 55  
 Line ≥3 60 36 24  
 Unknown 8 7 1  
  1. ECOG Eastern Cooperative Oncology Group, PS performance status, EGFR epidermal growth factor receptor, TKI tyrosine kinase inhibitor
  2. aExcept for this value, other values are all presented as the number of patients
  3. bAnalyzed by using χ2 test